Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children
Long-Term Immunogenicity Study of Inactivated EV71 Vaccine Produced in Vero Cells With Adjuvant AlPO4 in Children: Extension Study of Protocol CT-EV-21
Sponsor: Medigen Vaccine Biologics Corp.
A observational or N/A phase clinical study on Enterovirus 71 Human, this trial is completed. The trial is conducted by Medigen Vaccine Biologics Corp. and has accumulated 14 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Oct 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2022 — Oct 2022 [monthly]
Active Not Recruiting
▶ Show 9 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Apr 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2020 — Nov 2020 [monthly]
Active Not Recruiting
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2019 — Mar 2020 [monthly]
Not Yet Recruiting
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medigen Vaccine Biologics Corp.
For direct contact, visit the study record on ClinicalTrials.gov .